{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hiltonol%C2%AE&page=2",
    "query": {
      "intervention": "Hiltonol®",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hiltonol%C2%AE&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hiltonol%C2%AE&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T13:11:36.142Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05013216",
      "title": "Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "High Risk Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Cohort A: Patients at high risk of developing pancreatic cancer.",
          "type": "DRUG"
        },
        {
          "name": "Cohort B: Patients must have evidence of a pancreatic cystic neoplasm",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2022-04-11",
      "completion_date": "2031-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-09-30T13:11:36.142Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05013216"
    },
    {
      "nct_id": "NCT03262103",
      "title": "Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Intratumoral (IT) Poly ICLC 0.5 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intratumoral (IT) Poly ICLC 1.0 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intramuscular (IM) Poly ICLC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radical Prostatectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Ashutosh Kumar Tewari",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 13,
      "start_date": "2017-06-16",
      "completion_date": "2022-05-06",
      "has_results": false,
      "last_update_posted_date": "2022-09-10",
      "last_synced_at": "2026-09-30T13:11:36.142Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03262103"
    },
    {
      "nct_id": "NCT06564623",
      "title": "Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Biliary Tract Cancers"
      ],
      "interventions": [
        {
          "name": "mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)]",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2025-05-27",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-09-30T13:11:36.142Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06564623"
    },
    {
      "nct_id": "NCT03162562",
      "title": "The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer of Ovary",
        "Neoplasms, Ovarian",
        "Ovarian Cancer Stage IV",
        "Ovarian Cancer Recurrent",
        "Ovarian Cancer Stage III",
        "Ovary Cancer"
      ],
      "interventions": [
        {
          "name": "Oregovomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "CanariaBio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2017-05-30",
      "completion_date": "2020-11-05",
      "has_results": false,
      "last_update_posted_date": "2020-12-22",
      "last_synced_at": "2026-09-30T13:11:36.142Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Richmond, Virginia",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03162562"
    },
    {
      "nct_id": "NCT01245673",
      "title": "Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloma"
      ],
      "interventions": [
        {
          "name": "Prevnar- Pneumococcal Conjugate Vaccine (PCV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Activated/costimulated autologous T-cell",
          "type": "OTHER"
        },
        {
          "name": "Revlamid® (Lenalidomide)",
          "type": "DRUG"
        },
        {
          "name": "MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 28,
      "start_date": "2011-05-10",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2020-04-06",
      "last_synced_at": "2026-09-30T13:11:36.142Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01245673"
    },
    {
      "nct_id": "NCT02071095",
      "title": "Enhancement by Poly-ICLC During HIV-1 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV-1 Infected Adults With Chronic HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "Arm A: Poly-ICLC",
          "type": "DRUG"
        },
        {
          "name": "Arm B: Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nina Bhardwaj",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2014-04",
      "completion_date": "2016-07-26",
      "has_results": true,
      "last_update_posted_date": "2018-03-13",
      "last_synced_at": "2026-09-30T13:11:36.142Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02071095"
    },
    {
      "nct_id": "NCT02334735",
      "title": "A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "DC Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Montanide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly-ICLC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Nina Bhardwaj",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2015-07-01",
      "completion_date": "2020-07-15",
      "has_results": false,
      "last_update_posted_date": "2022-09-15",
      "last_synced_at": "2026-09-30T13:11:36.142Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02334735"
    },
    {
      "nct_id": "NCT06411691",
      "title": "KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "KRAS Vaccine with Poly-ICLC adjuvant",
          "type": "DRUG"
        },
        {
          "name": "Balstilimab",
          "type": "DRUG"
        },
        {
          "name": "Botensilimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2024-11-04",
      "completion_date": "2030-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-09-30T13:11:36.142Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06411691"
    },
    {
      "nct_id": "NCT02754362",
      "title": "A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Glioma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly-ICLC as immune adjuvant",
          "type": "DRUG"
        },
        {
          "name": "Keyhole limpet hemocyanin (KLH)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-11",
      "completion_date": "2019-06",
      "has_results": false,
      "last_update_posted_date": "2020-01-13",
      "last_synced_at": "2026-09-30T13:11:36.142Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02754362"
    },
    {
      "nct_id": "NCT02643303",
      "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Breast Cancer",
        "Sarcoma",
        "Merkel Cell Carcinoma",
        "Cutaneous T-Cell Lymphoma",
        "Melanoma",
        "Renal Cancer",
        "Bladder Cancer",
        "Prostate Cancer",
        "Testicular Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "Poly-ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ludwig Institute for Cancer Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2016-12-28",
      "completion_date": "2022-02-23",
      "has_results": true,
      "last_update_posted_date": "2022-12-02",
      "last_synced_at": "2026-09-30T13:11:36.142Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Lebanon, New Hampshire • Buffalo, New York + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02643303"
    }
  ]
}